Help us: Donate
Follow us on:
×

Menu

Back

Tag: Michael West

Dividing cells
A team of researchers, including Michael West of AgeX Therapeutics, has authored a review paper that posits a fundamental difference between "immortal" germline cells and "mortal" somatic cells. The two types of cells This review paper, which cites 175 other papers, goes back throughout history, discussing the very earliest scientific theories of aging. It talks...
EARD reception
Ending Age-Related Diseases 2019 is over, and the dust is starting to settle after what can only be described as a hugely successful event for our organization. This was our second year of running a conference, and once more, we focused on the research and investment areas of rejuvenation biotechnology. Totally sold out We wish...
Earlier this year, we hosted the Ending Age-Related Diseases 2018 conference at the Cooper Union in New York City. This conference was designed to bring together the best in the aging research and biotech investment worlds and saw a range of industry experts sharing their insights. Dr. Oliver Medvedik, LEAF vice president and Director of...
Today, we would like to share with you a talk by Dr. Michael West from AgeX Therapeutics, a company developing therapies to combat age-related diseases by encouraging the body to regenerate cells and tissues. On July 12th, we hosted our first conference, Ending Age-Related Diseases: Investment Prospects & Advances in Research, at the Frederick P....
SpeakerGroup_LEAFCooperConference2018
On July 12th, we hosted our first conference, Ending Age-Related Diseases: Investment Prospects & Advances in Research, at the Frederick P. Rose Auditorium, which is part of the Cooper Union campus in New York City. We are delighted to announce that the conference was a huge success with 160 attendees, a wide variety of speakers...
BRINGING REJUVENATION BIOTECHNOLOGY AND INVESTORS TOGETHER At the Frederick P. Rose Auditorium, Cooper Union in New York City, we will be hosting a special one-day conference focused on aging research and biotech investment. Developing therapies from initial concepts, through clinical testing, and ultimately to market takes a pipeline, and right now, that pipeline is being...